Clinical Trials Logo

Myeloproliferative Neoplasms clinical trials

View clinical trials related to Myeloproliferative Neoplasms.

Filter by:

NCT ID: NCT06313593 Not yet recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Start date: June 14, 2024
Phase: Phase 1
Study type: Interventional

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

NCT ID: NCT06291987 Not yet recruiting - Clinical trials for Myeloproliferative Neoplasms

Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs

MPN
Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.

NCT ID: NCT06034002 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

LIMBER
Start date: December 4, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

NCT ID: NCT05936359 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

LIMBER
Start date: September 25, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

NCT ID: NCT05444530 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Start date: July 21, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

NCT ID: NCT04866056 Terminated - Clinical trials for Myelodysplastic Syndromes

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Start date: September 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.

NCT ID: NCT04761770 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

Start date: February 15, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive. Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.

NCT ID: NCT04339400 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.

NCT ID: NCT03912064 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Start date: July 10, 2019
Phase: Phase 1
Study type: Interventional

In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF).

NCT ID: NCT03618485 Active, not recruiting - Clinical trials for Myeloproliferative Neoplasms

Registry of Patients With MPNs in Taiwan

Start date: April 1, 2017
Phase:
Study type: Observational [Patient Registry]

Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies with great variation in reported patient life expectancy and are characterized by a relatively indolent course which can be complicated by thromboembolic events and transformation to acute myeloid leukemia (AML). The MPNs in the 2016 World Health Organization (WHO) classification of myeloid neoplasms consist of polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) including prefibrotic/early stage and over fibrotic stage, chronic myeloid leukemia, other (rare) disorders such as chronic neutrophilic leukemia and chronic eosinophilic leukemia and MPN unclassifiable (MPN-U). The prevalence and genetic characteristics of patients with MPNs in Taiwan are still unknown. Molecular tests which are required for the diagnosis of MPNs are not available in many hospitals which hamper the accurate diagnosis and subtype classification of MPNs. Moreover, the information of current therapeutic strategy for MPNs in most medical centers in Taiwan is also not available. The purpose of this MPN registry is to collect clinical data, molecular characteristics, treatment details and response to therapy, occurrence of complications during the course, disease progression to secondary myelofibrosis from PV or ET and secondary AML (sAML) transformation as well as survival. The clinical and molecular data including the high molecular risk (HMR) genes will be examined and correlated with treatment outcomes in Taiwanese MPN patients. The Molecular Diagnostic Laboratory at Chang Gung Memorial Hospital-Linkou is a College of American Pathologists (CAP)-accredited lab which provides high quality of molecular genetic tests for hematologic malignancies. The three driver gene mutations are the major criteria for the diagnosis of MPN, the methodologies of mutational analyses have been well set up for the clinical use in this lab. In addition, this lab is also equipped with facilities for the detection of mutated genes which were recently identified as HRM category (presence of any of ASXL1, EZH2, SRSF2, IDH1 or IDH2), and mutations of other epigenetic regulators or splicing factors.